SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells.
about
Regulation of endodermal differentiation of human embryonic stem cells through integrin-ECM interactionsDifferentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overviewTissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytesProgramming and reprogramming a human heart cellInduced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screeningStem cell imaging: from bench to bedsideConsiderations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytesPluripotent stem cells in regenerative medicine: challenges and recent progressAdvances in cell culture: anchorage dependence.Functional cardiac tissue engineeringFACS-based isolation, propagation and characterization of mouse embryonic cardiomyocytes based on VCAM-1 surface marker expressionA massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytesGeneration of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cellsIdentification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expressionLet-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes.In Vitro Differentiation of First Trimester Human Umbilical Cord Perivascular Cells into Contracting Cardiomyocyte-Like Cells.Induced regeneration--the progress and promise of direct reprogramming for heart repair.Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypesModelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytesInhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardiumIdentification of human embryonic progenitor cell targeting peptides using phage displayA mass spectrometric-derived cell surface protein atlasHigh content screening for modulators of cardiac differentiation in human pluripotent stem cellsMicrofluidic bioreactor for dynamic regulation of early mesodermal commitment in human pluripotent stem cells.Label-free electrophysiological cytometry for stem cell-derived cardiomyocyte clusters.Parthenogenetic stem cells for tissue-engineered heart repair.Design and formulation of functional pluripotent stem cell-derived cardiac microtissues.Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNAMicrofluidic device generating stable concentration gradients for long term cell culture: application to Wnt3a regulation of β-catenin signaling.Combining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes.High-purity enrichment of functional cardiovascular cells from human iPS cells.Foxa2 identifies a cardiac progenitor population with ventricular differentiation potential.Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell TherapyiPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types.Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug TargetsHeparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin-Free Medium, Enabling Consistent Manufacture of CardiomyocytesGeneration of folliculogenic human epithelial stem cells from induced pluripotent stem cells.Platelet-derived growth factor receptor-alpha positive cardiac progenitor cells derived from multipotent germline stem cells are capable of cardiomyogenesis in vitro and in vivo.Constraining the Pluripotent Fate of Human Embryonic Stem Cells for Tissue Engineering and Cell Therapy - The Turning Point of Cell-Based Regenerative Medicine.Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
P2860
Q24303983-583CB698-F6AE-4C98-8A44-1B4A805AB3FCQ24618089-AF30E86D-9125-4C55-AE34-109A6CEC093EQ24623082-C877EAA8-E0E5-4B44-AA44-E74FF9872261Q26823933-EFF7E411-D435-4F5D-939D-2E60B9CD7BDBQ26828408-A5B003E5-4A06-4C7A-A71D-BCDD37CEABF3Q26861615-78161E15-914F-40B9-8464-7040DEE42A24Q26865173-98C64A43-82E6-42A3-966A-90098464109BQ26999292-1532B86E-C384-46AA-B84B-A99F4ABEBFC7Q27015670-C3B24D01-A70C-411B-8E06-BC8DD32061B9Q27024431-9DF03D5A-2607-49A5-842C-06D4828C810AQ27300128-B3F93ED2-580C-48E4-B110-9AF840C37867Q27301270-3E7E1D22-4049-48EB-B1D4-E82B6DE6275BQ27307424-7DEB77D1-580A-416A-9975-C6BDD757843FQ27320909-CFDDB964-BFFC-46E7-9ECC-AB1879EA7AFDQ27324739-25D9915B-C57E-41C1-A9BB-508E6F6D8111Q27349567-12B74503-F797-4523-9A0F-15A39D233814Q27687630-652DD586-11FD-46EB-ACAB-637EDA7A4231Q28081697-FE9CCA9B-3C4D-4ACA-835E-467DDDC225B8Q28255887-D302BC86-7683-453B-8253-996491C72EF2Q28305306-84FA93FF-4AFA-4008-8F28-E27CABB1E21AQ28487510-79D37330-D025-427B-9B10-5BF50F6D5579Q28546580-23B442A7-3DEA-4532-B700-C56A95A10021Q30390374-212C3C2C-D041-4974-A09F-522B7D5E59D6Q30531102-E50BB90E-12F6-436A-8D41-7D36AABC6419Q30533228-945055BA-2652-4442-B1A3-EE6FA6A69BB5Q30536576-32B8A0A2-C1B3-4B58-9667-371A2A10399FQ30559093-7E92F7CA-BD81-4D9B-9A8A-9A8E7A8DC353Q30561343-DFA51CD3-72E5-4BE6-BCBF-8FD0BC770AE7Q30584513-F2A1A3BF-5A9C-4C6C-A234-64FD76FB81ABQ30597186-BA1335C7-091C-4DE8-9A51-10205F070132Q30645777-9FCFB6DF-1922-42E7-BFDA-44308AAAC42EQ30839209-D3E2E5AE-CD7D-474A-8EB7-3D50CFD76F17Q31056955-9812DD25-EC84-48DA-B69B-3EB972ACFA22Q33559864-E614DEF1-D76A-4104-948C-94E9B883DCFEQ33722218-58544ED7-BB14-46AB-A41A-4ABEFA6CFD10Q33722559-4D5A2303-EAE6-4DA6-B661-A93C058E197AQ33725270-C49AC943-6997-494E-8E08-A7B0E928F43BQ33728080-F663FCB6-EFC9-4E19-9433-FE27CEAC9752Q33732794-B67554C0-C648-44B6-AA56-A0545754D5E9Q33821060-7B441C7E-C12A-46F5-A10D-C80188FF9B05
P2860
SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@en
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@nl
type
label
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@en
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@nl
prefLabel
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@en
SIRPA is a specific cell-surfa ...... human pluripotent stem cells.
@nl
P2093
P2860
P50
P356
P1433
P1476
SIRPA is a specific cell-surfa ...... m human pluripotent stem cells
@en
P2093
Anthony Gramolini
April M Craft
Edouard G Stanley
Nicole C Dubois
P2860
P2888
P304
P356
10.1038/NBT.2005
P577
2011-10-23T00:00:00Z